Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project.
Adolescent
Adult
California
/ epidemiology
Disease Progression
Ethnicity
Female
Health Status Disparities
Humans
Lupus Erythematosus, Systemic
/ diagnosis
Lupus Nephritis
/ diagnosis
Lupus Vasculitis, Central Nervous System
/ diagnosis
Male
Middle Aged
Population Surveillance
Prevalence
Prognosis
Race Factors
Racial Groups
Registries
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Young Adult
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
22
10
2018
accepted:
26
03
2019
pubmed:
23
5
2019
medline:
21
7
2020
entrez:
23
5
2019
Statut:
ppublish
Résumé
The California Lupus Surveillance Project (CLSP) is a population-based registry of individuals with systemic lupus erythematosus (SLE) residing in San Francisco County, California from 2007 to 2009, with a special focus on Asian/Pacific Islander and Hispanic patients. We used retrospective CLSP data to analyze racial and ethnic differences in lupus manifestations and in the timing and risk of developing severe manifestations. A total of 724 patients with SLE were retrospectively identified. Prevalence ratios (PRs) of SLE manifestations were calculated using Poisson regression models stratified by race/ethnicity and adjusted for sex, age at SLE diagnosis, and disease duration. We studied onset of severe SLE manifestations after SLE diagnosis using Kaplan-Meier methods to examine time-to-event and Cox proportional hazards regression models to estimate hazard ratios (HRs). White patients were the referent group in all analyses. African Americans, Asian/Pacific Islanders, and Hispanic patients had increased prevalence of renal manifestations (PR 1.74 [95% confidence interval (95% CI) 1.40-2.16], PR 1.68 [95% CI 1.38-2.05], and PR 1.35 [95% CI 1.05-1.74], respectively). Furthermore, African Americans had increased prevalence of neurologic manifestations (PR 1.49 [95% CI 1.12-1.98]), and both African Americans (PR 1.09 [95% CI 1.04-1.15]) and Asian/Pacific Islanders (PR 1.07 [95% CI 1.01-1.13]) had increased prevalence of hematologic manifestations. African Americans, Asian/Pacific Islanders, and Hispanic patients, respectively, had higher risk of developing lupus nephritis (HR 2.4 [95% CI 1.6-3.8], HR 4.3 [95% CI 2.9-6.4], and HR 2.3 [95% CI 1.4-3.8]) and thrombocytopenia (HR 2.3 [95% CI 1.1-4.4], HR 2.3 [95% CI 1.3-4.2], and HR 2.2 [95% CI 1.1-4.7]). Asian/Pacific Islander and Hispanic patients had higher risk of developing antiphospholipid syndrome (HR 2.5 [95% CI 1.4-4.4] and HR 2.6 [95% CI 1.3-5.1], respectively). This is the first epidemiologic study comparing lupus manifestations among 4 major racial and ethnic groups. We found substantial differences in the prevalence of several clinical SLE manifestations among racial/ethnic groups and discovered that African Americans, Asian/Pacific Islanders, and Hispanic patients are at increased risk of developing several severe manifestations following a diagnosis of SLE.
Identifiants
pubmed: 31115180
doi: 10.1002/acr.23887
pmc: PMC6872905
mid: NIHMS1020586
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
622-629Subventions
Organisme : NIAMS NIH HHS
ID : K24 AR074534
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP006486
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR070155
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP005120
Pays : United States
Organisme : ACL HHS
ID : U01DP005120
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019, American College of Rheumatology.
Références
J Am Soc Nephrol. 2007 Jan;18(1):244-54
pubmed: 17167111
Arthritis Rheum. 2001 Dec;44(12):2797-806
pubmed: 11762940
Lupus. 2010 Feb;19(2):119-29
pubmed: 19946032
Arthritis Rheumatol. 2014 Feb;66(2):369-78
pubmed: 24504809
Curr Rheumatol Rep. 2003 Oct;5(5):391-4
pubmed: 12967526
Arthritis Rheumatol. 2014 Feb;66(2):357-68
pubmed: 24504808
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
Semin Arthritis Rheum. 1989 Feb;18(3):189-97
pubmed: 2648578
J Clin Rheumatol. 2001 Jun;7(3):142-50
pubmed: 17039119
Kidney Int. 2006 May;69(10):1846-51
pubmed: 16598205
J Clin Invest. 1996 Mar 1;97(5):1348-54
pubmed: 8636449
Arthritis Rheum. 1998 Jul;41(7):1161-72
pubmed: 9663471
Medicine (Baltimore). 2004 Jan;83(1):1-17
pubmed: 14747764
Am J Med. 2002 Jun 15;112(9):726-9
pubmed: 12079714
Lupus. 2006;15(1):26-31
pubmed: 16482742
Arthritis Rheumatol. 2017 Oct;69(10):1996-2005
pubmed: 28891237
PLoS One. 2018 Jun 28;13(6):e0199003
pubmed: 29953444
J Rheumatol. 2012 Apr;39(4):759-69
pubmed: 22382348
Arthritis Rheumatol. 2017 Oct;69(10):2006-2017
pubmed: 28891252
Arthritis Rheum. 1990 Jan;33(1):37-48
pubmed: 2302266
J Rheumatol. 1990 Feb;17(2):220-4
pubmed: 2319521
Curr Rheumatol Rep. 2004 Dec;6(6):458-62
pubmed: 15527705
Lupus. 2016 Oct;25(11):1217-23
pubmed: 26921269
Lupus. 2011 May;20(6):561-7
pubmed: 21415256
Arthritis Rheumatol. 2014 Sep;66(9):2494-502
pubmed: 24891315